"...a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a safer, more durable anti-cancer effect..."
in vivo it gave almost no toxicity (so they say) due to precision delivery, which is great...
Embark Phase 3 clinical trial
Substandard Control Arm in Recently Published mCRPC trials
Started Phase 1 trial - RO7656594 yesterday
Info about ongoing Phase III PCa trials
